Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors

References

• Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369: 1961–1971.
   PubMed Web of Science ®Google Scholar
• Donders GGG, Bellen G, Mendling W. Management of recurrent vulvo-vaginal candidosis as chronic illness. Gynecol Obstet Invest 2010; 70: 306–321.
   PubMed Web of Science ®Google Scholar
• Ilkit M, Güzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol 2011; 37: 250–261.
   PubMed Web of Science ®Google Scholar
• Robinson SC, Nicholas WC, Lee DT, Wanklin JM, Zwicker B. The relationship of pregnancy, vaginal candidiasis and glucose metabolism. Can Med Assoc J 1967; 96: 583–585.
   PubMed Web of Science ®Google Scholar
• Roberts CL, Morris JM, Rickard KR, . Protocol for a randomised controlled trials of treatment of asymptomatic candidiasis for the prevention of preterm birth. BMC Preg Child 2011; 11: 19.
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr. First, do no harm. Pediatrics 2008; 121: 831–832.
   PubMed Web of Science ®Google Scholar
• Soong D, Einarson A. Vaginal yeast infections during pregnancy. Can Fam Phys 2009; 55: 255–256.
   PubMed Web of Science ®Google Scholar
• Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician 2004; 70: 2125–2132.
   PubMed Web of Science ®Google Scholar
• Zio C. A practical guide to dermatological drug use in pregnancy. Skin Ther Lett 2006; 11: 1–4.
   Google Scholar
• Federal Register. 1980; 44: 37434–37467.
   Google Scholar
• Sobel JD, Zervos M, Reed BD, . Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34–38.
   PubMed Web of Science ®Google Scholar
• Guzel AB, Ilkit M, Burgut R, Urunsak IF, Ozgunen FT. An evaluation of risk factors in pregnant women with Candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling. Mycopathologia 2011; 171: 25–36.
   Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
   Google Scholar
• Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. The CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180–195.
   PubMed Web of Science ®Google Scholar
• Biasoli MS, Tosello ME, Luque AG, Magaró HM. Adherence, colonization and dissemination of Candida dubliniensis and other Candida species. Med Mycol 2010; 48: 291–297.
   PubMed Web of Science ®Google Scholar
• Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 2001; 39: 2971–2974.
   PubMed Web of Science ®Google Scholar
• Rüchel R, Böning B, Borg M. Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme during infection in vitro. Infect Immun 1986; 53: 411–419.
   PubMed Web of Science ®Google Scholar
• Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouradia 1982; 20: 7–14.
   PubMedGoogle Scholar
• Lynch ME, Sobel JD. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994; 32: 267–274.
   PubMedGoogle Scholar
• Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia 2000; 151: 5–10.
   Web of Science ®Google Scholar
• Otero L, Fleites A, Méndez FJ, Palacio V, Vázquez F. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Eur J Clin Microbiol Infect Dis 1999; 18: 59–61.
   PubMed Web of Science ®Google Scholar
• Richter SS, Galask RP, Messer SA, . Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 43: 2155–2162.
   PubMed Web of Science ®Google Scholar
• Gross NT, Arias ML, Moraga M, Baddasarow Y, Jarstrand C. Species distribution and susceptibility to azoles of vaginal yeasts isolated prostitutes. Infect Dis Obstet Gynecol 2007; 2007: 82412.
   PubMedGoogle Scholar
• Ozcan SK, Budak F, Yücesoy G, Susever S, Willke A. Prevalence, susceptibility profile and proteinase production of yeast causing vulvovaginitis in Turkish women. APMIS 2006; 114: 139–145.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction- impact of two decades. Mycoses 2011; 54: 34–38.
   PubMed Web of Science ®Google Scholar
• Fan SR, Liu XP. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 2011; 54: 501–505.
   PubMed Web of Science ®Google Scholar
• Candido RC, Toloi RT, Franceschini SA, Garcia FR, Minto ECM. In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species. Mycopathologia 1998; 144: 15–20.
   PubMed Web of Science ®Google Scholar
• Mathema B, Cross E, Dun E, . Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001; 33: e23–27.
   Web of Science ®Google Scholar
• Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22: 726–727.
   PubMed Web of Science ®Google Scholar
• Van Slike KK, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J Obstet Gynecol 1981; 141: 145–148.
   PubMed Web of Science ®Google Scholar
• Shubair M, Larsen B. Growth inhibition of Candida albicans and other medically important yeasts by vaginal contraceptive methods. Gynecol Obstet Invest 1990; 29: 67–70.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24: 649–652.
   PubMed Web of Science ®Google Scholar
• Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189: 1297–1300.
   PubMed Web of Science ®Google Scholar
• Lian CH, Liu WD. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007; 50: 383–390.
   PubMed Web of Science ®Google Scholar
• Taylor BN, Staib P, Binder A, . Profile of Candida albicans- secreted aspartic proteinase elicited during vaginal infection. Infect Immun 2005; 73: 1828–1835.
   PubMed Web of Science ®Google Scholar
• Yildirim Z, Kilic N, Kalkanci A. Fluorometric determination of acid proteinase activity in Candida albicans strains from diabetic patients with vulvovaginal candidiasis. Mycoses 2011; 54: e463–467.
   PubMed Web of Science ®Google Scholar
• Kalkanci A, Bozdayi G, Biri A, Kustimur S. Distribution of secreted aspartyl proteinases using a polymerase chain reaction assay with SAP specific primers in Candida albicans isolates. Folia Microbiol 2005; 50: 409–413.
   PubMed Web of Science ®Google Scholar
• Costa CR, Passos XS, Souza LKH, . Differences in exoenzyme production and adherence ability of Candida spp. isolates from catheter, blood and oral cavity. Rev Inst Med Trop Sao Paulo 2010; 52: 139–143.
   PubMed Web of Science ®Google Scholar
• Tosun I, Aydin F, Kaklikkaya N, Erturk M. Induction of secretory aspartyl proteinase of Candida albicans by HIV-1 but not HSV-2 or some other microorganisms associated with vaginal environment. Mycopathologia 2005; 159: 213–218.
   PubMed Web of Science ®Google Scholar
• Sacristán B, Blanco MT, Galán-Ladero A, . Aspartyl proteinase, phospholipase, hemolytic activities and biofilm production of Candida albicans isolated from bronchial aspirates of ICU patients. Med Mycol 2011; 49: 94–97.
   PubMed Web of Science ®Google Scholar
• Tsang CSP, Chu FCS, Leung WK, . Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393–1398.
   PubMed Web of Science ®Google Scholar
• Zhu W, Filler SG. Interactions of Candida albicans with epithelial cells. Cell Microbiol 2010; 12: 273–282.
   PubMed Web of Science ®Google Scholar
• Paiva LC, Donatti L, Patussi EV, Svizdinski TI, Lopes-Consolaro ME. Scanning electron and confocal scanning laser microscopy imaging of the ultrastructure and viability of vaginal Candida albicans and non-albicans species adhered to an intrauterine contraceptive device. Microsc Microanal 2010; 16: 537–549.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Takano M, Murakami M, . Characterization of a haemolytic factor from Candida albicans. Microbiology 1999; 145: 689–694.
   PubMed Web of Science ®Google Scholar